Instituto de Diagnostico SA
Instituto de Diagnostico SA provides diagnostic services and operates in the healthcare facilities and services industry, generating revenue primarily through its diagnostic operations.
Business. Instituto de Diagnostico SA (INDISA.SN) is a healthcare services and equipment company operating within the healthcare facilities and services industry. The firm generates service revenue and is headquartered in Chile, with its primary listing on the Santiago Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Instituto de Diagnostico SA (INDISA.SN) is a healthcare services and equipment company operating within the healthcare facilities and services industry. The firm generates service revenue and is headquartered in Chile, with its primary listing on the Santiago Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Instituto de Diagnostico SA maintains a market price of 2700.0, with a market capitalization of 414,261,718,200.0. The company's price-to-earnings ratio is 26.45, and its price-to-book ratio is 2.0, indicating a moderate valuation relative to its book value. The enterprise value to EBITDA ratio is 14.26, and the enterprise value to revenue ratio is 1.83, suggesting a relatively low valuation in terms of revenue.
The company's profitability is reflected in its return on equity of 7.56% and return on assets of 3.83%. These figures are compared against the industry's preferred metrics, indicating that the company is performing in line with or slightly below the median for its sector. The gross profit margin is 25.95%, and the operating margin is 12.85%, which are key indicators of the company's efficiency in converting revenue into profit.
In terms of geographic and segment exposure, the company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. The company operates as a single segment, and its revenue is not diversified across multiple geographic regions. This concentration may pose a risk if the domestic market experiences economic downturns.
The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current and next fiscal years. The company's capital expenditure is negative, indicating that it is generating more cash from operations than it is spending on new assets. This suggests a conservative approach to capital spending and a focus on maintaining liquidity.
The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of concern is the negative net cash position after subtracting total debt, which may affect the company's ability to meet short-term obligations. The company's debt-to-equity ratio is 0.48, and its current ratio is 1.18, indicating a moderate level of leverage and a relatively strong short-term liquidity position.
Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company has not issued any new shares recently, and there are no indications of upcoming dilutive events. The company's financial statements and disclosures are consistent with its historical performance, and there are no material risks disclosed in recent filings.
- Instituto de Diagnostico SA has a moderate valuation with a price-to-earnings ratio of 26.45 and a price-to-book ratio of 2.0.
- The company's profitability is in line with industry standards, with a return on equity of 7.56% and a return on assets of 3.83%.
- The company's revenue is primarily concentrated in its domestic market, with no significant international operations.
- The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted.
- The company has a medium level of liquidity risk and a low level of dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Instituto de Diagnostico SA Market data — financials · 2026-05-28